Effect of Two Unique Nanoparticle Formulations on the Efficacy of a Broadly Protective Vaccine Against Pseudomonas Aeruginosa
AuthorHowlader, Debaki R
Varisco, David J
Dietz, Zackary K
Walton, Sierra P
Ratnakaram, Siva Sai Kumar
Gardner, Francesca M
Ernst, Robert K
Picking, William D
Picking, Wendy L
JournalFrontiers in Pharmacology
PublisherFrontiers Media S.A.
MetadataShow full item record
AbstractPseudomonas aeruginosa is an opportunistic pathogen responsible for a wide range of infections in humans. In addition to its innate antibiotic resistance, P. aeruginosa is very effective in acquiring resistance resulting in the emergence of multi-drug resistance strains and a licensed vaccine is not yet available. We have previously demonstrated the protective efficacy of a novel antigen PaF (Pa Fusion), a fusion of the type III secretion system (T3SS) needle tip protein, PcrV, and the first of two translocator proteins, PopB. PaF was modified to provide a self-adjuvanting activity by fusing the A1 subunit of the heat-labile enterotoxin from Enterotoxigenic E. coli to its N-terminus to give L-PaF. In addition to providing protection against 04 and 06 serotypes of P. aeruginosa, L-PaF elicited opsonophagocytic killing and stimulated IL-17A secretion, which have been predicted to be required for a successful vaccine. While monomeric recombinant subunit vaccines can be protective in mice, this protection often does not transfer to humans where multimeric formulations perform better. Here, we use two unique formulations, an oil-in-water (o/w) emulsion and a chitosan particle, as well as the addition of a unique TLR4 agonist, BECC438 (a detoxified lipid A analogue designated Bacterial Enzymatic Combinatorial Chemistry 438), as an initial step in optimizing L-PaF for use in humans. The o/w emulsion together with BECC438 provided the best protective efficacy, which correlated with high levels of opsonophagocytic killing and IL-17A secretion, thereby reducing the lung burden among all the vaccinated groups tested.
Rights/TermsCopyright © 2021 Howlader, Das, Lu, Hu, Varisco, Dietz, Walton, Ratnakaram, Gardner, Ernst, Picking and Picking.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/16593
- Development of a Broadly Protective, Self-Adjuvanting Subunit Vaccine to Prevent Infections by <i>Pseudomonas aeruginosa</i>.
- Authors: Das S, Howlader DR, Zheng Q, Ratnakaram SSK, Whittier SK, Lu T, Keith JD, Picking WD, Birket SE, Picking WL
- Issue date: 2020
- A Live <i>Salmonella</i> Vaccine Delivering PcrV through the Type III Secretion System Protects against Pseudomonas aeruginosa.
- Authors: Aguilera-Herce J, García-Quintanilla M, Romero-Flores R, McConnell MJ, Ramos-Morales F
- Issue date: 2019 Apr 17
- Modified needle-tip PcrV proteins reveal distinct phenotypes relevant to the control of type III secretion and intoxication by Pseudomonas aeruginosa.
- Authors: Sato H, Hunt ML, Weiner JJ, Hansen AT, Frank DW
- Issue date: 2011 Mar 29
- Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against <i>Pseudomonas aeruginosa</i>.
- Authors: Wan C, Zhang J, Zhao L, Cheng X, Gao C, Wang Y, Xu W, Zou Q, Gu J
- Issue date: 2019
- Anti-PcrV IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound models.
- Authors: Ranjbar M, Behrouz B, Norouzi F, Mousavi Gargari SL
- Issue date: 2019 Dec